FDA Approves Drug That Targets Brain Cancer Mutation That May Delay Need for Radiation and Chemotherapy
Photo by Elizabeth Cook/Johns Hopkins A new drug for a type of brain cancer, called IDH-mutant low-grade glioma, was approved this month by the US Food and Drug Administration—a promising treatment that resulted from a genetic discovery made at the Center for Johns Hopkins Cancer 16 years ago. . The drug, called vorasidenib, is a … Read more